Brain-targeted peptide work: nootropics, neuroprotection, stroke recovery.
Casey Halpern's Nature Medicine case study recorded nucleus-accumbens activity in a single patient on tirzepatide. Activity was suppressed early, then returned at 5 months alongside renewed cravings.